Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Einzel- vs. Dreifach-Hyaluronsäure bei Kniearthrose (DR-HAKOA)

3. November 2026 aktualisiert von: University of Erlangen-Nürnberg Medical School

Wirkungen und Sicherheit von Einzel- gegenüber Dreifach-Hyaluronsäure-Injektionen bei der Behandlung von Kniearthrose

The goal of this clinical trial is to directly compare two hyaluronic acid injection protocols in adults with knee osteoarthritis: a single intra-articular injection of Innoryos 2.5% (Single-Shot) and a three-week injection series of Innoryos 2.2% (Triple-Shot). The study aims to determine whether the single injection provides comparable safety, pain relief, and improvement in knee function to the triple-injection protocol.

The main questions are:

  • How do the single-shot and triple-shot protocols compare in terms of pain reduction and functional improvement?
  • How do their safety and tolerability profiles compare?
  • What medical problems occur with each protocol? Participants (n = 46) will receive either the single 4.8 ml injection or three weekly 2 ml injections. They will attend clinic visits at baseline, Week 6, Week 12, and Week 24 for assessments including WOMAC score, 7-day pain diary, functional and strength tests, and MRI scans of the knee.

This single-center, partially blinded, randomized study will provide a direct comparison of the two HA injection protocols, assessing whether the single-shot approach is as safe and effective as the triple-shot regimen, while potentially offering a more convenient, patient-friendly treatment.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Background:

Knee osteoarthritis (gonarthrosis) is a prevalent degenerative joint disease characterized by cartilage loss, joint pain, stiffness, and functional impairment, which significantly affects mobility and quality of life. Intra-articular injections of hyaluronic acid (HA) are a well-established conservative therapy to reduce pain, improve function, and potentially delay surgical interventions. Various HA formulations and injection protocols exist, differing in molecular weight, concentration, and dosing schedules. Optimizing treatment in terms of efficacy, safety, patient convenience, and cost-effectiveness remains a key clinical goal.

Objective:

This study aims to compare the safety, tolerability, and efficacy of a single intra-articular injection of Innoryos 2.5% (Single-Shot) with a standard three-week injection regimen of Innoryos 2.2% (Triple-Shot) in adults with moderate to severe knee osteoarthritis. The primary focus is on safety and pain reduction, with secondary outcomes including functional improvement, leg muscle strength, and structural assessment of the knee joint via MRI.

Study Design:

This is a single-center, randomized, partially blinded, parallel-group clinical intervention study including 46 participants. Patients are randomized using block randomization stratified by baseline WOMAC total score to ensure balanced distribution of baseline pain and functional impairment. Patients and treating physicians are aware of treatment allocation, while all personnel performing functional tests, MRI assessments, data entry, and statistical analyses are blinded to minimize bias.

Participants:

Adults aged 40-70 years with radiographically confirmed moderate to severe knee osteoarthritis, experiencing knee pain for at least three months and on at least 50% of days in the prior month. Key exclusion criteria include grade 4 osteoarthritis, non-osteoarthritic knee pain, other rheumatic diseases, recent HA or corticosteroid injections, recent trauma or surgery, coagulopathies, autoimmune disorders, pregnancy or lactation, and contraindications for MRI.

Interventions:

  • Single-Shot Group: One intra-articular injection of Innoryos 2.5% (4.8 ml)
  • Triple-Shot Group: Three intra-articular injections of Innoryos 2.2% (2 ml each) at weekly intervals

Outcomes:

The primary outcome is total WOMAC score. Secondary outcomes include WOMAC subscales, VAS pain diary, functional performance, leg muscle strength, MRI-detected structural changes, and safety/tolerability parameters.

Assessments:

Participants are assessed at baseline, Week 6, Week 12, and Week 24.

  • WOMAC questionnaire (baseline, Week 6, Week 12, and Week 24): Pain, stiffness, and functional limitation
  • Pain diary (VAS) (baseline, Week 6, Week 12, and Week 24): Daily for 7 days at each assessment (~1 min/day)
  • Functional and strength tests (baseline, Week 6, Week 12): Chair Stand Test, Timed Up and Go Test, isokinetic leg press (~30 min per session)
  • MRI (baseline, Week 6, Week 12): Baseline and Week 12 for structural assessment (~90 min including functional tests)
  • Safety monitoring: Adverse events, medication use, compliance, drop-outs

Significance:

This study provides high-quality evidence for the direct comparison of single-shot versus triple-shot HA injection protocols in knee osteoarthritis. By using stratified randomization based on baseline WOMAC total score and blinded assessment of outcomes, the trial ensures unbiased evaluation. Demonstration of comparable safety and efficacy of the single-shot regimen could offer a more convenient, patient-friendly, and potentially safer therapeutic option, optimizing conservative management for patients with knee osteoarthritis.

intra-articular injection of Innoryos 2.5% (Single-Shot) with a standard three-week injection regimen of Innoryos 2.2% (Triple-Shot) in adults with moderate to severe knee osteoarthritis. The primary focus is on safety and pain reduction, with secondary outcomes including functional improvement, leg muscle strength, and structural assessment of the knee joint via MRI.

Study Design:

This is a single-center, randomized, partially blinded, parallel-group clinical intervention study including 46 participants. Patients are randomized using block randomization stratified by baseline WOMAC total score to ensure balanced distribution of baseline pain and functional impairment. Patients and treating physicians are aware of treatment allocation, while all personnel performing functional tests, MRI assessments, data entry, and statistical analyses are blinded to minimize bias.

Participants:

Adults aged 40-70 years with radiographically confirmed moderate to severe knee osteoarthritis, experiencing knee pain for at least three months and on at least 50% of days in the prior month. Key exclusion criteria include grade 4 osteoarthritis, non-osteoarthritic knee pain, other rheumatic diseases, recent HA or corticosteroid injections, recent trauma or surgery, coagulopathies, autoimmune disorders, pregnancy or lactation, and contraindications for MRI.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

46

Phase

  • Phase 2
  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Erlangen, Deutschland, 91052
        • Institute of Radiology, University Hospital Erlangen

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

40 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults aged 40-70 years
  • Radiographically confirmed moderate to severe knee osteoarthritis
  • Knee pain for ≥3 months
  • Pain on ≥50% of days in past 30 days
  • Able to provide informed consent

Exclusion Criteria:

  • Grade 4 osteoarthritis (full-thickness cartilage loss)
  • Non-osteoarthritic knee pain
  • Other rheumatic diseases (e.g., rheumatoid arthritis, fibromyalgia)
  • HA injection <6 months or corticosteroid injection <3 months in target knee
  • Recent trauma or surgery of affected knee (<6 months)
  • Coagulopathy or bleeding disorder
  • Autoimmune or relevant systemic disease
  • Dermatologic infection at injection site
  • Pregnancy or lactation
  • Opioid or oral corticosteroid use
  • Contraindications to MRI (pacemaker, intracorporeal metal, claustrophobia)
  • Expected absence during study period or noncompliance

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Three intra-articular HA injections

Three intra-articular injections of Innoryos 2.2% (2 ml each) in the knee joint at weekly intervals

Therapy with intra-articular injections of hyaluronic acid (HA). Three intra-articular injections of Innoryos 2.2% (2 ml per injection) administered into the affected knee joint at weekly intervals.

Experimental: One intra-articular HA injection

One intra-articular injection of Innoryos 2.5% (4.8 ml) in the knee joint

Therapy with a single intra-articular injection of hyaluronic acid (HA). One intra-articular injection of Innoryos 2.5% (4.8 ml per injection) administered into the affected knee joint at weekly intervals.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
WOMAC questionnaire total score
Zeitfenster: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Total score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing overall pain, stiffness, and physical function of the knee joint

At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
WOMAC questionnaire pain subscore
Zeitfenster: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Pain subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing pain of the knee joint

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
WOMAC questionnaire stiffness subscore
Zeitfenster: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Stiffness subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing stiffness of the knee joint

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
WOMAC questionnaire physical function subscore
Zeitfenster: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Physical function subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing pain of the knee joint

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
7-day pain assessment using visual analog scale (VAS)
Zeitfenster: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Participants will record their knee pain daily using a Visual Analog Scale (VAS) as part of a 7-day pain diary at each assessment period. The VAS is a straight 100 mm line, anchored by "no pain" at 0 mm and "worst imaginable pain" at 100 mm. Participants indicate their current knee pain intensity each day by marking a point on the line that best represents their pain.

The diary is completed for seven consecutive days to capture fluctuations in pain intensity during daily activities. The daily VAS scores are recorded and later averaged to calculate a weekly mean pain score.

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
Maximum isokinetic leg extension strength
Zeitfenster: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

Participants' leg muscle strength and functional performance are assessed using an isokinetic leg press (Physiomed, Laipersdorf, Germany). Before testing, participants complete a 5-minute warm-up on a cross-trainer to prepare the muscles and reduce injury risk.

Following the warm-up, two maximal test sessions are conducted, each consisting of 6 repetitions at a velocity of 0.6 meters per second (m/s). During each attempt, participants perform the leg press extension movement with maximal effort. The highest peak force achieved during the extension in each session is recorded and used for analysis.

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
30-Second Chair Stand Test (30s CST) - Assessment of Lower Limb Function:
Zeitfenster: At baseline, at 6 weeks, at 12 weeks, at 24 weeks

The 30-Second Chair Stand Test measures lower body strength, endurance, and functional mobility. Participants sit on a standard chair with arms crossed over the chest. When instructed, they stand up fully and sit back down repeatedly for 30 seconds.

The total number of full stands completed within 30 seconds is recorded. A higher number of repetitions indicates better lower limb strength and functional performance.

At baseline, at 6 weeks, at 12 weeks, at 24 weeks
Knee MRI and T2 Mapping - Assessment of Joint Structures
Zeitfenster: At baseline, at 12 weeks, at 24 weeks

Magnetic Resonance Imaging (MRI) is used to assess structural changes in the knee joint and evaluate the integrity of cartilage and other joint tissues. Participants undergo a non-invasive, radiation-free MRI scan of the affected knee at baseline and 12 weeks after treatment.

The MRI protocol includes high-resolution imaging of joint structures, such as cartilage, menisci, ligaments, and subchondral bone. Additionally, T2 mapping is performed to quantify the T2 relaxation time of articular cartilage, which reflects the water content and collagen organization. Areas of increased T2 values indicate cartilage degeneration or changes in cartilage composition, while decreases or stabilization suggest maintenance or improvement of cartilage health.

At baseline, at 12 weeks, at 24 weeks

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Compliance and Drop-Out
Zeitfenster: up to 24 weeks

Compliance refers to the degree to which participants adhere to the assigned injection protocol and scheduled study visits. For the Single-Shot group, compliance is assessed by confirming that participants receive the planned single 4.8 ml injection at baseline. For the Triple-Shot group, compliance is assessed by verifying that participants receive all three weekly 2 ml injections according to the study schedule. Compliance is documented in the study records and serves as a measure of treatment adherence and feasibility of the respective protocols.

Drop-Out refers to participants who withdraw from the study before completion or fail to attend follow-up assessments at the scheduled time points (baseline, Week 6, Week 12, Week 24). Reasons for drop-out, including adverse events, personal choice, or loss to follow-up, are recorded. Drop-out rates are analyzed as an endpoint to evaluate the acceptability, tolerability, and practicality of each

up to 24 weeks
Medication Use - Analgesic Tracking
Zeitfenster: Up to 24 weeks

Participants record their use of pain medications during the 7-day pain diary period, which accompanies the daily Numeric Rating Scale (NRS) for knee pain. Each day, participants document:

The type of pain medication taken The dosage The timing of administration

Up to 24 weeks
Adverse Effects - Safety Endpoint
Zeitfenster: Up to 24 weeks

Adverse effects are monitored to assess the safety and tolerability of the hyaluronic acid injection protocols. Participants are instructed to report any adverse events or reactions following the injections. Specifically:

Short-term monitoring: Participants record any adverse effects daily for 7 days after each injection. This includes local reactions at the injection site (e.g., pain, swelling, redness) as well as any systemic symptoms (e.g., fatigue, fever).

Long-term monitoring: Adverse effects are also tracked throughout the entire study duration.

All reported adverse events are documented, classified, and analyzed according to severity, duration, and possible relation to the treatment.

Up to 24 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Simon von Stengel, PhD, Institute of Radiology, University Hospital Erlangen, Germany

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Januar 2026

Primärer Abschluss (Geschätzt)

15. Dezember 2026

Studienabschluss (Geschätzt)

31. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

2. Januar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. Januar 2026

Zuerst gepostet (Tatsächlich)

20. Januar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. Januar 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 25-275_1-Bm

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data (IPD) from this study will not be shared publicly in order to comply with data protection regulations in Germany (GDPR) and the study's data protection consent. Only aggregated and anonymized results will be reported in publications or study summaries. No personal identifiers, contact information, or sensitive participant data will be disclosed.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .